About
Ancilia Bio develops CRISPR-based technologies to engineer beneficial bacteria with immunity against destructive viruses, enabling the creation of live biotherapeutics and bacterial products for therapeutics, agriculture, and industrial biotechnology.
Explore Ancilia Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.